Home / Expertise / Life Sciences & Healthcare
Life sciences picture - microscope

Life Sciences & Healthcare

Hong Kong

As a participant in the lifesciences and healthcare industry, you know that discovery and innovation are key to finding lasting health solutions. Yet due to the highly regulated nature of the industry, you - a corporate, investor or start-up - must overcome complex administrative, compliance and liability hurdles before your products and services can come to market.

With more than 300 lawyers, patent attorneys, scientists and academics across CMS and the support of the Lifesciences Asia-Pacific Network (LAN), we understand the scientific and commercial as well as the legal imperatives affecting your business.

Our experts, many of whom have worked in-house in your sector, have developed a shared capability in the areas of pharmaceuticals, biotechnology, medical devices and diagnostics. With active memberships in the major industry associations such as the ABPI, ABHI, BIVDA, PAGB, EUCOMED and EFPIA, we help shape the legal frameworks impacting the lifesciences sector.

We regularly advise our clients on their day to day operational needs such as support with public sector procurement, patent prosecution and enforcement, commercial agreements, tax and transfer pricing, and regulatory advice. Equally, when you need lifesciences specialist advice for strategic agreements, planning a corporate transaction or embarking on litigation (whether product liability or otherwise), we have a team that is well versed in the industry issues to help you.

Read more Read less

Feed

Show only
20 April 2021
COV­ID-19 vac­cin­a­tion and test­ing in Hong Kong - em­ploy­ment law per­spect­ive
Vac­cin­a­tion 1. What op­tions does the em­ploy­er have to en­cour­age em­ploy­ees to be vac­cin­ated? Can the em­ploy­er provide a fin­an­cial in­cent­ive to em­ploy­ees?  There are no gen­er­al re­stric­tions pre­vent­ing...
Comparable
02 October 2020
BRI - View from APAC
The Asia-Pa­cific re­gion (APAC) has seen ex­tens­ive Belt and Road (BRI) in­vest­ment already, and prom­ises much more.But our sur­vey of BRI par­ti­cipants in APAC re­veals un­ex­pec­ted levels of am­bi­val­ence about some as­pects of BRI pro­jects.Can these po­ten­tial dif­fi­culties be tackled in a way that will ad­dress con­cerns about is­sues such as trans­par­ency and sus­tain­ab­il­ity, and en­cour­age the great­er in­volve­ment of in­ter­na­tion­al busi­nesses that China hopes to see? And how are the un­pre­ced­en­ted prob­lems of 2020, in­clud­ing the glob­al pan­dem­ic and trade dis­putes, af­fect­ing the pro­spects of BRI?Our APAC re­port looks at is­sues in­clud­ing:Dif­fi­culties in BRI pro­jects ex­per­i­enced by APAC par­ti­cipants, and the po­ten­tial for resolv­ing these.The ef­fects of Cov­id-19 on BRI.Mit­ig­at­ing BRI risk and man­aging dis­putes.Po­ten­tial trends in the fin­an­cing of BRI pro­jects.The sec­tors at­tract­ing the most in­terest among BRI par­ti­cipants.The im­pact of BRI 2.0.
11 May 2021
AI in Life Sci­ences
Ar­ti­fi­cial in­tel­li­gence is not new: the term it­self was coined over 60 years ago. However, the con­ver­gence of data volume, pro­cessing power and tech­nic­al cap­ab­il­ity has con­vinced many that the AI era...